Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 5 de 5
Filtrer
1.
Aust N Z J Obstet Gynaecol ; 64(3): 269-276, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38189187

RÉSUMÉ

BACKGROUND: Pregnancy in kidney transplant recipients has become increasingly common. However, pregnancy carries higher risks to these patients compared to the general population. AIMS: To describe pregnancy outcomes in kidney transplant recipients. MATERIALS AND METHODS: We conducted a single-centre retrospective cohort study of kidney transplant recipients who delivered after 20 weeks gestation at a quaternary hospital in Victoria, Australia, between 2000 and 2022 inclusive. RESULTS: The study included 37 pregnancies from 27 patients, accounting for 38 infants. Over half of recorded pregnancies occurred in the past five years (56.8%, n = 21). There were high rates of pre-existing hypertension (75.7%, n = 28). Pregnancy-induced hypertension and pre-eclampsia were common antenatal complications (21.6%, n = 8 and 48.6%, n = 18 respectively). Soluble fms-like tyrosine kinase-1 / placental growth factor ratios were elevated in all patients who developed severe pre-eclampsia (16.2%, n = 6). The median gestational age at birth was 36.4 weeks (range 20-40.4, Q1 32.9, Q3 37.6) and 59.5% (n = 22) of births were preterm. Unplanned caesarean without labour was the most common mode of birth (35.1%, n = 13). The overall caesarean rate was 62.1% (n = 23). Post-partum haemorrhage complicated over half of pregnancies (56.8%, n = 21). Fifty percent (n = 19) of infants were admitted for neonatal care, in particular neonatal intensive care, and had low birthweights under 2500 g. While there was a transient deterioration in kidney function, there was no graft rejection within one year of birth. CONCLUSIONS: Clinicians should consider the high rates of pre-existing hypertension, preterm birth, and caesarean birth when counselling and managing pregnant kidney transplant recipients.


Sujet(s)
Transplantation rénale , Issue de la grossesse , Humains , Femelle , Grossesse , Études rétrospectives , Adulte , Complications de la grossesse/épidémiologie , Pré-éclampsie/épidémiologie , Hypertension artérielle gravidique/épidémiologie , Victoria/épidémiologie , Nouveau-né , Césarienne/statistiques et données numériques , Naissance prématurée/épidémiologie , Jeune adulte
2.
Aust N Z J Obstet Gynaecol ; 62(2): 332-335, 2022 04.
Article de Anglais | MEDLINE | ID: mdl-35040486

RÉSUMÉ

Pregnancy following renal transplantation is increasingly common. Overall pregnancy outcomes are favourable; however, specific transplant-related risks do exist. In particular, the risk of caesarean delivery is much higher in renal transplant recipients when compared to the general obstetric population. This is owing to the necessity for preterm delivery in cases of severe and early-onset pre-eclampsia and/or fetal growth restriction. We describe two recent cases of renal transplant injury at caesarean delivery at our institution, a tertiary/quaternary obstetric service, which highlight the potential operative risks associated with abdominal surgery. We propose a standardised approach in the care of transplant recipients undergoing caesarean delivery which is aimed at minimising harm and increasing patient safety.


Sujet(s)
Transplantation rénale , Pré-éclampsie , Naissance prématurée , Césarienne/effets indésirables , Femelle , Humains , Nouveau-né , Transplantation rénale/effets indésirables , Pré-éclampsie/étiologie , Grossesse , Issue de la grossesse/épidémiologie
3.
BMJ ; 362: k3546, 2018 09 04.
Article de Anglais | MEDLINE | ID: mdl-30181338

RÉSUMÉ

OBJECTIVE: To determine whether intravenous oxytocin is more effective than intramuscular oxytocin at preventing postpartum haemorrhage at vaginal delivery. DESIGN: Double blind placebo controlled randomised trial. SETTING: University affiliated maternity unit in the Republic of Ireland. PARTICIPANTS: 1075 women aged 18 years or older, at term with a singleton pregnancy who were aiming for a vaginal delivery with an actively managed third stage of labour. INTERVENTIONS: Women were allocated to an intravenous bolus of oxytocin (10 IU in 1 mL given slowly over one minute) and placebo intramuscular injection (1 mL 0.9% saline) or an intramuscular bolus of oxytocin (10 IU in 1 mL) and placebo intravenous injection (1 mL 0.9% saline given slowly over one minute) at vaginal delivery. Allocation was by a secure web based randomisation service with masking of participants and clinicians to the trial intervention. MAIN OUTCOME MEASURES: The primary outcome was postpartum haemorrhage (PPH, measured blood loss ≥500 mL). Secondary outcomes were severe PPH (measured blood loss ≥1000 mL), need for blood transfusion, admission to a high dependency unit, and side effects to oxytocin. RESULTS: Between 4 January 2016 and 13 December 2017, 1075 women were randomised and 1035 (96.3%) included in the primary and secondary analyses (517 in the intravenous oxytocin group and 518 in the intramuscular oxytocin group). The incidence of PPH was not significantly lower in the intravenous group (18.8%, 97/517) compared with intramuscular group (23.2%, 120/518): adjusted odds ratio 0.75 (95% confidence interval 0.55 to 1.03). The incidence of severe PPH, however, was significantly lower in the intravenous group (4.6%, 24/517) compared with intramuscular group (8.1%, 42/518): 0.54 (0.32 to 0.91) as was the need for blood transfusion (1.5% v 4.4%, 0.31, 0.13 to 0.70) and admission to a high dependency unit (1.7% v 3.7%, 0.44, 0.20 to 0.98). The number needed to treat to prevent one case of severe PPH was 29 (95% confidence interval 16 to 201) and to prevent one case of blood transfusion was 35 (20 to 121). The incidence of side effects to oxytocin was not increased in the intravenous group compared with intramuscular group (4.1% v 5.2%, 0.75, 0.42 to 1.35). CONCLUSION: Intravenous oxytocin for the third stage of labour results in less frequent severe PPH, blood transfusion, and admission to a high dependency unit than intramuscular oxytocin, and without excess side effects. TRIAL REGISTRATION: Current Controlled Trials ISRCTN14718882.


Sujet(s)
Accouchement (procédure)/normes , Ocytociques/administration et posologie , Ocytocine/administration et posologie , Hémorragie de la délivrance/prévention et contrôle , Administration par voie intraveineuse , Adolescent , Adulte , Transfusion sanguine/statistiques et données numériques , Femelle , Humains , Incidence , Injections musculaires , Injections veineuses , Irlande/épidémiologie , Ocytociques/usage thérapeutique , Ocytocine/effets indésirables , Ocytocine/usage thérapeutique , Hémorragie de la délivrance/épidémiologie , Hémorragie de la délivrance/mortalité , Grossesse , Résultat thérapeutique , Jeune adulte
4.
Ir J Med Sci ; 187(3): 789-794, 2018 Aug.
Article de Anglais | MEDLINE | ID: mdl-29299762

RÉSUMÉ

BACKGROUND: High-grade serous carcinoma (HGSC) is the most common tubo-ovarian cancer. The fallopian tube harbours the precursor lesion: serous tubal intraepithelial carcinoma (STIC). Bilateral salpingo-oophorectomy is an effective risk-reducing surgical (RRS) strategy for breast cancer susceptibility gene mutation carriers (BRCAm). The value of RRS in those without defined genetic risk is unknown but these women represent a substantial cohort in prophylactic surgical practice. METHODS: This is a retrospective review of RRS at an Irish university teaching hospital. RESULTS: One hundred and thirty women underwent RRS; group 1 = 46 BRCAm; group 2 = 19 BRCAm negative/65 genetic status unknown. Group 1 had one occult HGSC. Group 2 had no STIC or cancers and were older and more likely to have hysterectomy and benign pathology. Other pathologies included serous tubal intraepithelial lesions (STIL) (2), p53 signatures (2), endometriosis (6), fibroids/adenomyosis (4) and atypical endometrial hyperplasia (1). CONCLUSION: More than 60% of women undergoing RRS were BRCAm negative or untested. Counselling of high-risk women without defined germline mutations remains a challenge for gynaecologists because the likelihood of removing STIC lesions or occult invasive cancer is low. Removal of coincidental pathology may give added value to RRS in these women.


Sujet(s)
Tumeurs de l'ovaire/chirurgie , Adulte , Sujet âgé , Femelle , Humains , Irlande , Adulte d'âge moyen , Tumeurs de l'ovaire/ethnologie , Études rétrospectives , Comportement de réduction des risques
5.
JIMD Rep ; 41: 29-36, 2018.
Article de Anglais | MEDLINE | ID: mdl-29292490

RÉSUMÉ

Glutaric aciduria type 1 (GA1) is an autosomal recessive rare disorder caused by mutations in the GCDH gene resulting in deficiency of glutaryl-CoA dehydrogenase, leading to accumulation of the amino acids lysine, hydroxylysine and tryptophan and other metabolites. The phenotypic spectrum of disease is broad. Stress caused by infection and fever and possibly pregnancy may lead to worsening of the signs and symptoms, often with uncertain recovery.We describe a case of a female patient with GA1 who had two clinically uneventful pregnancies.At the age of 11 she was diagnosed with GA1 by family screening. The cultured skin fibroblast showed reduced glutaryl-CoA dehydrogenase activity (0.16 mg protein per min).The initial diagnostic urine glutaric acid level for this patient was 1,784 µmol/mmol creatinine. Mutation analysis showed compound heterozygosity for the p.(Gly185Arg), c.553G>A in exon 7 and p.(Arg402Trp), c.1204C.T in exon 11 mutations of the GCDH.Her pregnancy at the age of 23 was complicated by pre-eclampsia and required treatment with beta-blockers. Four years later the second pregnancy was uncomplicated. The management plan during the caesarean section included intravenous dextrose and lipid infusions. The patient rapidly recovered from both surgeries.Both babies have had normal development to date. On newborn screening, plasma acylcarnitine showed a transient increase in glutarylcarnitine, and the urine organic acid analysis showed a trace of 3-hydroxyglutarylcarnitine, likely to be of maternal transfer.The multidisciplinary team, consisting of metabolic, dietetic and obstetric care providers, have responsibility to ensure the risk of acute decompensation in pregnant GA1 women is minimal.

SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE